Insomniacs are known to have a higher risk of developing hypertension, but less attention has been focused on patients with hypertension with respect to the further aggravation of the hypertensive states because of poor quality sleep. 1-4 Indeed, a great many of hypertensive patients suffer additional distress because of poorer quality sleep, 5-7 and the degree of poor sleep quality is associated with the severity of the hypertension. [7] [8] [9] [10] These observations suggest the possibility that hypertension and the disrupted sleep might share a common etiology, namely adrenergic overdrive. However, the pathophysiology behind sleep disturbance related to essential hypertension is much less well understood.
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when animals are treated with a β-agonist or β-antagonist. 21, 22 A central action affecting the sleep or arousal centers has been suggested, but these studies do not provide information about any effect on sympathetic activity. More importantly, the involvement of adrenergic pathways in the sleep disturbance of SHR remains unknown.
Although cardiovascular variability analysis is an indirect measurement of autonomic function, its efficiency and convenience have helped to gain popularity recently. The highfrequency power and the normalized low-frequency power (LF%) of heart rate variability reflect cardiac vagal and sympathetic modulation, respectively, although the low-frequency power of blood pressure variability (BLF) reflects vascular sympathetic modulation. 23, 24 To reduce interference that may affect the animal's behavior, in this study, physiological signals were collected by telemetry. The aim of the present study was to test the hypothesis that sleep disturbance among SHR can be alleviated by antagonizing the adrenergic overdrive.
Methods
Animal preparation. Experiments were carried out on 8-to 10-week-old male SHR (n = 35) and Wistar-Kyoto (WKY) rats (n = 6). The rats were obtained from the Animal Center of National Yang-Ming University of Taiwan under the guidelines established by the Position of the American Heart Association on Research Animal Use. They were raised in a soundattenuated room with a 12:12 light-dark cycle (lights on from 08:30 am to 08:30 pm) and at an appropriate temperature (22 ± 2 °C) and humidity (40-70%) control. The experimental procedures were approved by the Institutional Animal Care and Use Committee of National Yang-Ming University.
The animals were implanted with electrodes under pentobarbital anesthesia (50 mg/kg, i.p.). 25, 26 Two stainless steel screws were driven bilaterally into the skull overlaying the parietal cortex (2 mm posterior to and ±2 mm lateral to the bregma), and a reference electrode was implanted 2 mm caudal to the lambda. Two seven-strand stainless steel microwires were inserted into the dorsal neck muscles to record electromyogram (EMG). Electrocardiogram was recorded via a pair of microwires placed dorsally under the skin. A telemetry transmitter (TA11PA-C40, Data Sciences, St. Paul, MN) was implanted in the abdominal aorta to collect arterial pressure signals. After surgery, the rats were housed individually for 1 week to allow recovery.
Protocol.
The experiments started at least seven days after surgery. On day 1, a wireless sensor was mounted on the head of the animal for habituation. On day 2, the polysomnographic recording started at the beginning of light on (08:30 am), and then 1 h later (09:30 am), the SHR and WKY rats were given an i.p. injection of saline (saline, 1 ml/kg). On day 4, the recording was performed during the same time window, but this time the SHR was given an i.p. injection (as singleton) of one of the five hypotensive agents selected randomly (a selective α1-blocker, prazosin, 1 mg/kg, n = 8; a non-selective α-blocker, phentolamine, 10 mg/kg, n = 6; a selective β1-blocker, atenolol, 20 mg/kg, n = 7; a non-selective β-blocker, propranolol, 10 mg/kg, n = 7; a vascular smooth muscle relaxant, hydralazine, 10 mg/kg, n = 7; all from Sigma-Aldrich, St Louis, MO) and the WKY rats were injected with prazosin (1 mg/kg i.p., n = 6). The doses used have been reported to have some effects on the sleep-wake cycle of rats, and their hypotensive effects are thought to be comparable. 20, 27, 28 Rats sleep primarily during the light phase of the day and therefore the study focused on the daytime effects of these drugs. Two hours after injection the blood pressure lowering effect was found at its most stable and consistent, and therefore the data to be analyzed were collected starting 2 h after injection and lasted until the end of the light phase.
Measurements. The electrophysiological signals were recorded by a wireless sensor (KY4C, K&Y Lab, Taipei, Taiwan, size: 25 × 21 × 13 mm, weight: 8.6 g) developed by our laboratory, and performance of the telemetry system has been validated. 29 The electroencephalogram (EEG), EMG, and electrocardiogram signals were amplified 1,000, 1,000, and 500-fold, respectively, and filtered at 0.16-48 Hz, 34-103 Hz, and 0.72-103 Hz, respectively. 30 The EEG, EMG, and electrocardiogram signals were synchronously digitized by an analog-digital converter at different sampling rates (125, 250, and 500 Hz, respectively). The digitized signals were then wirelessly transmitted to a digital data recorder (KY3, K&Y Lab) at a radio frequency of 2.4 GHz. The arterial pressure signals were wirelessly transmitted to its specific receiver (CATALOG# 272-6001, Data Sciences), and were reconstructed into continuous waveforms by a pulse-interval to voltage converter (KY2, K&Y Lab). Next the arterial pressure waveforms were digitized (at 500 Hz) synchronously with the electrophysiological signals using the same data recorder (KY3). All digitized data were stored in a flash memory card for subsequent off-line analysis.
Sleep analysis. Sleep-wake stages were classified based on the EEG and EMG records. 11, 31 Continuous power spectral analysis was applied to the EEG and EMG signals using a Hamming window of 16 s (50% overlap), from which the mean power frequency of the EEG (MPF) and the power magnitude of the EMG were quantified. For each time epoch (8 s), the conscious state was defined as active waking (AW) if the corresponding MPF and EMG power were above a pre-defined MPF threshold (T MPF ) and EMG power threshold (T EMG ), respectively; as QS if the MPF and EMG power were below the T MPF and the T EMG , respectively; and as paradoxical sleep (PS) if the MPF was above the T MPF and the EMG power was below the T EMG . If the MPF was below the T MPF and the EMG power was above the T EMG , an erroneous epoch was identified and excluded from analysis. To define the threshold, first, the recorded data were cut into 5-h segments. Second, the 5-h time series of MPF underwent a histogram analysis, from which two separate populations that were respectively related to the AW/PS complex and QS could be identified. Therefore the T MPF could be set to discriminate these two populations. Third, the histogram of the EMG time series also had two populations, which were respectively original contributions Adrenergic Overdrive and Sleep Disturbance in SHR related to AW and the QS/PS complex. Therefore T EMG could be set to discriminate these two populations. Fourthly, the T MPF and T EMG were manually fine-tuned by an experienced rater. A sleep-wake stage was formed when there were at least six consecutive identical epochs, and an interruption was marked when consecutive epochs were less than six. 11 To quantify the architecture of sleep-wake stages, the time (total time of a given stage within the analysis period), number (bout number of a given stage) and duration (average bout duration of a given stage) were calculated. Quality of sleep was assessed by the delta power of the QS stages and the interruptions of the QS and PS stages. In addition, stage transitions were also identified and enumerated (AW to QS transition, A-Q; AW to PS transition, A-P; QS to AW transition, Q-A; QS to PS transition, Q-P; PS to AW transition, P-A; PS to QS transition, P-Q). Stage transitions provide information about the tendency of a given stage to transition to another stage.
Cardiovascular variability analysis.
The analytical procedures for cardiovascular variability have been detailed previously. 25, 31 In brief, the mean arterial pressure was obtained by integration of the arterial pulse contour. The R-R interval was estimated continuously from the digitized electrocardiogram signals. The stationary mean arterial pressure and R-R interval were resampled and interpolated at 64 Hz to provide continuity in the time domain, and then were truncated into 16-s time segments (1,024 points) with 50% overlap. These sequences were analyzed by fast Fourier transform after application of a Hamming window. The low-frequency power (frequency range: 0.06-0.6 Hz) of the mean arterial pressure spectrogram was used as an index for sympathetic vasomotor activity. The high-frequency power (frequency range: 0.6-2.4 Hz) and the normalized lowfrequency power (frequency range: 0.06-0.6 Hz) of the R-R interval spectrogram provided estimates for cardiac vagal and cardiac sympathetic modulation, respectively. 23, 24, 32 Statistical analysis. For correction of their skewed distributions, BLF and high-frequency power were transformed using natural logarithms. 33 Because of the small sample size, comparisons of sleep structure and cardiovascular measures between two sets of data were carried out using the Wilcoxon rank sum tests (two different hypotensive agents) or the Wilcoxon signed-rank tests (hypotensive agents vs. saline). The one sample Wilcoxon signed-rank tests were applied to test difference values (relative to saline) against zero change. When the difference values were compared simultaneously between the four hypotensive treatments, we used the Kruskal-Wallis tests; to isolate the regional differences, the post hoc Dunn's tests were applied for comparisons between two different hypotensive treatments. Statistical significance was assumed for P < 0.05. Data are expressed as mean ± SEM.
results
An example of a recording obtained from a saline-injected rat during the light cycle is presented in Figure 1a . Transient reversible cardiovascular changes were noted when the animal was being injected with saline. Quiet sleep was continually interrupted by brief paradoxical sleep breaks with sometimes large intrusions by waking periods; arterial pressure and heart rate fluctuated along with these stage transitions. The linear regression analysis showed that vascular sympathetic activity (BLF) gauged during quiet sleep was closely correlated with many dimensions of the quiet sleep (Figure 2) . BLF was positively related to the number and interruption and negatively to total time and duration (Figure 2B ), whereas cardiac sympathetic activity (LF%) was irrelevant to any measure of the QS architecture (Figure 2A) . Therefore, one may surmise that higher α-adrenergic activity (vascular) but not higher β-adrenergic activity (cardiac) contributes to the fragmented sleep pattern found in SHR. To test this postulation, several adrenergic antagonists targeting α-or β-adrenoceptors were administered.
Under α1-adrenergic antagonism, there was a remarkable drop in blood pressure (mean arterial pressure) and BLF after the prazosin injection as compared with the saline injection, but LF% and high-frequency power remained unaffected (Figure 1b) . The decreases in blood pressure and BLF were significant for all stages (Figure 3b) , with a reciprocal acceleration of heart rate during sleep (Figure 3a) . During quiet sleep, as compared with saline, BLF and high-frequency power were significantly decreased with an unchanged level of LF% (P = 0.58), and the decrease in BLF was the largest among the four treatments (χ 2 = 19.24, P < 0.05, post hoc vs. propranolol and atenolol, P < 0.05, Table 1 ). At the same time, the disrupted QS structure was reversed in a manner such that total time and duration were lengthened and interruptions were reduced (Figures 1b and 3c) ; the change in QS time was the largest among the four antagonist treatments (χ 2 = 15.98, P < 0.05, post hoc vs. the other three treatments, P < 0.05, Table 1 ). In addition, the A-Q and P-A transitions were significantly increased and decreased, respectively (Figure 3d) . The increased A-Q transitions suggest that more AW stages entered QS stages, which might contribute to a prolonged QS time; furthermore, the increased A-Q and decreased P-A transitions could explain the reduced AW time ( Table 2) .
Norepinephrine release from sympathetic nerve endings is under the inhibitory control of presynaptic α2-adrenoceptors, 34 so α2-adrenergic blockade should be able to antagonize the effect of α1-adrenergic blockade by indirectly activating the α1-adrenergic pathway. We tested if the QS-modifying effect of prazosin was also under this control. During quiet sleep under non-selective α-sympathetic blockade by phentolamine, blood pressure, BLF, and LF% were significantly decreased ( Table 1) . However, the decrease in BLF was less than that induced by selective α-1 blockade (P < 0.05, Table 1 ). The QS pattern and stage transition were not affected (except for a decrease in A-Q transition, Table 1 ). Therefore, α2-adrenergic activity appears to counteract the effect of α1-adrenergic activation to modify quiet sleep.
To determine if β-adrenergic pathways are involved in the modulation of sleep-wake cycles, the β1-antagonist atenolol was administered. Compared with saline treatment, original contributions Adrenergic Overdrive and Sleep Disturbance in SHR the atenolol injection induced a decrease in LF% and blood pressure, and an decrease in heart rate across all sleep-wake stages (Supplementary Figure S1a,b, online) , although BLF was depressed only during wakefulness (Supplementary  Figure S1b, online) . During quiet sleep, LF% was significantly decreased, but QS structure was not altered (Supplementary Figure S1c,d, online) . To further test if complete blockade of the β-adrenergic pathway might elicit any QS-modifying effect, we treated the animals with the non-selective β-adrenergic antagonist propranolol. When both β1-and β2-adrenoceptors were blocked, blood pressure and LF% were significantly decreased as compared with saline; nonetheless, the alterations in QS pattern and stage transition that could be observed during α1 blockade were still absent (Tables 1 and 2) .
Variations in blood pressure alone might affect sleep structure. 35, 36 To confirm that prazosin does not modulate sleep structure indirectly via a lowering of blood pressure, we compared prazosin injection with hydralazine injection, which lowers blood pressure by directly relaxing vascular smooth muscles rather than by inhibiting α1-adrenergic activity. The effects of prazosin treatment and hydralazine treatment are expressed as different values with respect to saline treatment and are compared in Figure 4 . The percentage decreases in blood pressure for both groups were comparable regardless of the sleep-wake stage (hydralazine vs. prazosin: AW, −12.0 ± 1.4 vs. −12.1 ± 2.0, P = 0.56; QS, −8.4 ± 1.4 vs. −7.1 ± 1.4, P = 0.56; PS, −9.2 ± 1.6 vs. −7.8 ± 1.7, P = 0.36) (Figure 4a) ; however, modifications in terms of QS architecture (Figure 4b ) and stage transitions (Figure 4c) were completely absent when the animals were treated with hydralazine.
Finally, to determine if the effects of α1-adrenergic antagonism on sleep were specific to SHR, a group of WKY rats was treated with prazosin. During sleep, blood pressure was significantly decreased by prazosin as compared with saline, as were R-R interval and BLF. With respect to QS structure, time (P = 0.12), number (P = 0.25), duration (P = 0.12), interruptions (P = 0.12) and delta power (P = 0.75) were not significantly changed by prazosin (Supplementary Figure S2c, online) . Transitions between stages after prazosin treatment were also not significantly different from the saline treatment (A-Q, P = 1.00; A-P, P = 0.11; Q-A, P = 1.00; Q-P, P = 0.07; P-A, P = 0.08; P-Q, P = 0.12; Supplementary Figure S2d, online) . Therefore, in terms of the effect on sleep, prazosin appears to be beneficial when given to SHR, but has no effect when given to WKY rats. discussion SHR is sensitive to external interference, 37 so a telemetry recording system allowing for continuous recording with two days later, the animal was treated with prazosin (1 mg/kg). Mean arterial pressure was lower than saline, with a significantly decreased low-frequency power of arterial pressure variability (bLF) (also note the lower density of bLF in the blood pressure power spectrogram). Quiet sleep (QS) time and duration were prolonged as compared with the saline treatment. AW, active waking; HF, high-frequency power of heart rate variability; HPSD, rr power spectrogram; LF%, normalized low-frequency power of heart rate variability; ln, natural logarithm; MAP, mean arterial pressure; PS, paradoxical sleep; rr, r-r intervals.
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minimal artificial disturbance; the use of such a system for sleep research in this study is especially necessary with this strain of rat. We found an association between measures of QS quality in SHR and vascular sympathetic activity during this sleep stage, so we surmise that α1-adrenergic activity modulates QS architecture in the SHR. This hypothesis was confirmed using pharmacological manipulation of the adrenergic system, which showed that QS quality was improved only in the presence of a selective α1 blockade. This sleep-modulating effect is opposed by an α2-adrenergic blockade and is independent of any hypotensive effect, because lowering blood pressure by treatment with a direct vasodilator had no effect on QS architecture. Moreover, the beneficial effect on sleep is present in SHR but not in WKY rats. Therefore, our finding highlights the importance of the α1-adrenergic pathway in mediating sleep disturbance among SHR. Previous pharmacological studies have tested the modulating effects of various adrenergic agents on sleep-wake cycles in normotensive animals. Prazosin (1 mg/kg, i.p.) administered to Wistar rats has been shown to promote quiet sleep but shortened wakefulness. 18 The QS-facilitating effect of α1-antagonists is supported by the action of α1-and α2-agonists, which respectively decrease and increase quiet sleep, 20, 38, 39 and also by the offsetting effect of simultaneous blockade of α1-and α2-adrenoceptors by phentolamine. 18 With respect to β-adrenergic influence, in contrast, atenolol or propranolol elicited an insignificant effect on quiet sleep. 21, 27, 40 In addition to demonstrating the QS-promoting effects of prazosin among SHR, our results further suggest that prazosin might improve sleep quality by increasing transitions from wakefulness to sleep and reducing transitions from sleep to wakefulness, as well as by ameliorating sleep interruptions. original contributions
Norepinephrine is one of the main neurotransmitters in the monoaminergic arousal system and acts to promote wakefulness in conjunction with the cholinergic system and orexinergic neurons. 41, 42 The noradrenergic neurons in the locus coeruleus and the A1/A2 brainstem project to the preoptic area of the hypothalamus, which is known to be involved in sleep regulation. The locus coeruleus has been suggested to be the primary site where drugs acting at α1-or α2-adrenoceptors Values represent mean ± SEM. AW, active waking; A-P, AW to PS transition; A-Q, AW to QS transition; BLF, low-frequency power of arterial pressure variability; HF, high-frequency power of heart rate variability; LF%, normalized low-frequency power of heart rate variability; MAP, mean arterial pressure; PS, paradoxical sleep; P-A, PS to AW transition; P-Q, PS to QS transition; Q-A, QS to AW transition; Q-P, QS to PS transition; RR, R-R intervals. *P < 0.05 vs. zero change, one sample Wilcoxon signed-rank test. work to affect sleep, 43 an example being prazosin, which is known to be able to cross the blood brain barrier. 44 In addition, adrenergic agonists or antagonists also act on other wakefulness-promoting regions, such as the medial septal area and the medial preoptic area, 45, 46 as well as sleep-promoting regions that receive abundant adrenergic innervation, such as the preoptic area. 47 In patients with essential hypertension, the concentration of norepinephrine in cerebrospinal fluid and plasma is elevated. 12, 13 In SHR, noradrenergic activity in various brain areas is increased, including the prefrontal cortex, 28 the paraventricular nucleus of the hypothalamus, 48 and various nuclei in the brainstem. 16, 17 Therefore, in addition to contributing to hypertensive pathophysiology, this central noradrenergic abnormality likely serves to disrupt normal sleep-wake cycles. There are some limitations to the present study. First, cardiovascular variability analysis did not directly measure autonomic activity, so it might not be applicable to the hydralazine-treated animals. Under hydralazine treatment, the vascular smooth muscles were directly relaxed, and thus the blood pressure variability was unable to reveal corresponding changes in sympathetic activity. Second, the insignificant effect of atenolol on the sleep-wake cycle could be in part because of its inability to readily cross the blood brain barrier, and in this circumstance intraventricular administration may help confirm its effects. Third, the hypotensive agents were always given after saline, so we are unable to exclude a temporal effect. Lastly, any extension of the current findings to other models of hypertension should be made with great caution, particularly when the model does not have sympathetic overdrive as the ontogeny.
Hypertensive patients usually sleep more poorly, and inadequate sleep has been found to impair cardiovascular regulation and has been identified as a significant risk factor for hypertension. 3, 4, 49, 50 We found that the α1-adrenergic antagonism may reverse, at least partially, the poor sleep quality of SHR, indicating that the adrenergic overdrive of the hypertensive state contributes to poor quality of sleep in this population. This mechanism may lead to a vicious cycle among SHR whereby an enhanced norepinephrine spillover leads to sleep disturbance, which in turn aggravates the adrenergic overdrive. Our results also indicate that α1-adrenergic overdrive is likely a common etiology for hypertension and sleep disturbance that is associated with hypertension, which suggests a potential site at which this vicious cycle can be broken up. Although the ontogeny of α1-adrenergic overdrive in hypertensives needs further investigation, we hope that our findings help to provide clues for antihypertensive treatments if sleep problems are an issue of concern in hypertensive patients. and PS to AW (P-A) transitions were noted in prazosin treatment, but no significant change in stage transition was present in hydralazine treatment. *P < 0.05 vs. hydralazine group, Wilcoxon rank sum test; †P < 0.05 vs. zero change, one sample Wilcoxon signed-rank test. AW, active waking; A-P, AW to PS transition; ln, natural logarithm; P-Q, PS to QS transition; PS, paradoxical sleep; Q-A, QS to AW transition; Q-P, QS to PS transition.
